Have a feature idea you'd love to see implemented?
Let us know!
LBPH Longboard Pharmaceuticals Inc
Price (delayed)
$59.8
Market cap
$2.33B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.23
Enterprise value
$2.31B
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena to advance a portfolio of
Highlights
The company's debt fell by 3.3% QoQ
The quick ratio has soared by 88% YoY but it has contracted by 24% from the previous quarter
The EPS is up by 8% year-on-year but it is down by 3.7% since the previous quarter
The net income has dropped by 50% year-on-year and by 18% since the previous quarter
The equity has contracted by 7% from the previous quarter
Key stats
What are the main financial stats of LBPH
Market
Valuations
Earnings
Shares outstanding
39.05M
Market cap
$2.33B
Enterprise value
$2.31B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.45
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$76.34M
EBITDA
-$76.34M
Free cash flow
-$65.93M
Per share
Balance sheet
Liquidity
EPS
-$2.23
Free cash flow per share
-$1.69
Book value per share
$7.07
Revenue per share
$0
TBVPS
$7.62
Total assets
$297.01M
Total liabilities
$21.82M
Debt
$3.73M
Equity
$275.19M
Working capital
$274.68M
Debt to equity
0.01
Current ratio
15.97
Quick ratio
15.72
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-30.9%
Return on equity
-33%
Return on invested capital
-36.5%
Return on capital employed
-27.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LBPH stock price
How has the Longboard Pharmaceuticals stock price performed over time
Intraday
0.05%
1 week
0.18%
1 month
0.67%
1 year
1,358.54%
YTD
891.71%
QTD
79.42%
Financial performance
How have Longboard Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.58M
Net income
-$76.34M
Gross margin
N/A
Net margin
N/A
Longboard Pharmaceuticals's operating income has plunged by 65% YoY and by 20% from the previous quarter
The net income has dropped by 50% year-on-year and by 18% since the previous quarter
Growth
What is Longboard Pharmaceuticals's growth rate over time
Valuation
What is Longboard Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 8% year-on-year but it is down by 3.7% since the previous quarter
The P/B is 135% above the last 4 quarters average of 3.6
The equity has contracted by 7% from the previous quarter
Efficiency
How efficient is Longboard Pharmaceuticals business performance
The ROIC has soared by 70% YoY and by 14% from the previous quarter
LBPH's return on equity has surged by 60% year-on-year and by 11% since the previous quarter
The ROA has soared by 58% YoY and by 10% from the previous quarter
Dividends
What is LBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LBPH.
Financial health
How did Longboard Pharmaceuticals financials performed over time
The quick ratio has soared by 88% YoY but it has contracted by 24% from the previous quarter
Longboard Pharmaceuticals's current ratio has surged by 84% YoY but it has decreased by 24% QoQ
The company's debt is 99% lower than its equity
The equity has contracted by 7% from the previous quarter
The company's debt fell by 3.3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.